Children’s Hospital Oakland converts to Masimo Rainbow Place Pulse CO-Oximetry technology Masimo , the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Children’s Hospital & Research Center Oakland offers completed its system-wide conversions to Masimo Rainbow Collection Pulse CO-Oximetry technology. Standardizing to Masimo Rainbow Collection makes Children’s Medical center Oakland the first children’s hospital to pioneer new continuous noninvasive blood monitoring features hospital-wide–allowing earlier and better clinical decisions without the intermittent pain and wait associated with drawing blood. By transforming to Masimo Rainbow Place, Children’s Medical center Oakland clinicians will gain all the benefits and Measure-Through Movement capabilities of Masimo Place pulse oximetry, along with the breakthrough creativity of the first-ever constant and non-invasive hemoglobin monitoring ) technology.Deborah Schrag from the Dana-Farber Tumor Institute in Boston and her colleagues let the cat from the bag in a recent study they published in the New England Journal of Medication , which uncovered that a lot of cancer patients do not know that their disease won’t be cured because of chemotherapy. According to the study’s findings, as much as 69 % of terminally ill lung malignancy sufferers and 81 % of terminally ill colorectal sufferers do not know that chemotherapy medicines are fully not capable of curing their cancers. Though they are said to help some malignancy patients live slightly much longer lives potentially, chemotherapy drugs admittedly do not stop the development or spread of cancers cells and tumors, which means most of the individuals who opt for the treatment are not being told the entire truth about its main shortcomings.